FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324136609> ?p ?o ?g. }

• W4324136609 endingPage "506" @default.
• W4324136609 startingPage "506" @default.
• W4324136609 abstract "506 Background: Despite response to systemic therapy, few metastatic urothelial carcinoma (mUC) patients (pts) achieve durable responses. Mutations in the COMPASS-related proteins KMT2D, KMT2C, and KDM6A are found in 66% of UC patients suggesting histone regulation may be an acquired mechanism of tumor viability. We previously found regression of UC in mice when treated with EZH2 inhibitor, tazemetostat. In vivo administration of tazemtostat enhanced the immune response with direct regulation of cytokines and antigen recognition machinery (MHCI and MHCII). We hypothesized that restoration of epigenetic imbalance, combined with immunotherapy, may improve outcomes in mUC pts. Methods: ETCTN 10183 (NCT03854474) is a pilot study evaluating the efficacy of tazemetostat 800 mg BID + pembrolizumab 200 mg every 3 weeks for cisplatin-refractory (Cohort A) or cisplatin/chemo-ineligible advanced UC (Cohort B) pts, with N=12 pts in each cohort. The primary objective is to identify the recommended phase two dose (RP2D) of tazemetostat in combination with pembrolizumab. Secondary objectives include RECIST-based response rate, safety, and progression-free survival. The maximum planned treatment duration is 2 years. Translational objectives include defining total and COMPASS-related genes tumor mutational burden, tumor subtyping, TCR clonality, T cell infiltration, and PDL-1 expression. Results: In the safety lead-in phase, 6 mUC pts were treated. There were no dose-limiting toxicities (DLTs). The RP2D for tazemetostat was established at 800 mg BID. Here we report results of fully accrued cohort A (N=12); 67% males, 33% females, 83% white, 8.3% Black, and 25% Hispanic/Latino ethnicity. The primary sites of UC were: bladder (n=9, 75%), renal pelvis (n=2, 17%), and ureter (n=1, 8.3%). The median (interquartile range, IQR) time since primary diagnosis was 1.1 years (0.7, 1.9); 11/12 patients had non-nodal metastatic disease; 10/12 had 1 or more visceral/bone metastasis. Median number of treatment cycles was 5 (IQR: 3-11; range 1-35). Median duration on protocol treatment was 12 weeks (IQR: 7-30; range 3-107 weeks). Three pts had treatment related grade 3/4 AEs: grade 4 sepsis (n=1), grade 3 lymphopenia (n=2); anemia, increased alkaline-phosphatase, and HSV oral infection (n=1 each). Best response was partial response (PR) in 3 pts (25%) and 3 (25%) had stable disease. Median PFS was 3.1 months (95%CI: 2.3-NA), and median overall survival was 8.0 months (95% CI: 4.7 – NA). Conclusions: The RP2D dose for tazemetostat is 800 mg + 200 mg Pembrolizumab q 3 weeks. The combination was feasible, well tolerated, and resulted in durable responses in poor-risk chemo-refractory UC patients. Clinical trial information: 03854474 ." @default.
• W4324136609 created "2023-03-15" @default.
• W4324136609 creator A5009872882 @default.
• W4324136609 creator A5010551367 @default.
• W4324136609 creator A5022594161 @default.
• W4324136609 creator A5041126882 @default.
• W4324136609 creator A5042000897 @default.
• W4324136609 creator A5046042179 @default.
• W4324136609 creator A5066717552 @default.
• W4324136609 creator A5074582149 @default.
• W4324136609 creator A5074874280 @default.
• W4324136609 creator A5082413734 @default.
• W4324136609 date "2023-02-20" @default.
• W4324136609 modified "2023-09-23" @default.
• W4324136609 title "A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183)." @default.
• W4324136609 doi "https://doi.org/10.1200/jco.2023.41.6_suppl.506" @default.
• W4324136609 hasPublicationYear "2023" @default.
• W4324136609 type Work @default.
• W4324136609 citedByCount "0" @default.
• W4324136609 crossrefType "journal-article" @default.
• W4324136609 hasAuthorship W4324136609A5009872882 @default.
• W4324136609 hasAuthorship W4324136609A5010551367 @default.
• W4324136609 hasAuthorship W4324136609A5022594161 @default.
• W4324136609 hasAuthorship W4324136609A5041126882 @default.
• W4324136609 hasAuthorship W4324136609A5042000897 @default.
• W4324136609 hasAuthorship W4324136609A5046042179 @default.
• W4324136609 hasAuthorship W4324136609A5066717552 @default.
• W4324136609 hasAuthorship W4324136609A5074582149 @default.
• W4324136609 hasAuthorship W4324136609A5074874280 @default.
• W4324136609 hasAuthorship W4324136609A5082413734 @default.
• W4324136609 hasConcept C121608353 @default.
• W4324136609 hasConcept C126322002 @default.
• W4324136609 hasConcept C143998085 @default.
• W4324136609 hasConcept C2777701055 @default.
• W4324136609 hasConcept C2780057760 @default.
• W4324136609 hasConcept C71924100 @default.
• W4324136609 hasConcept C72563966 @default.
• W4324136609 hasConceptScore W4324136609C121608353 @default.
• W4324136609 hasConceptScore W4324136609C126322002 @default.
• W4324136609 hasConceptScore W4324136609C143998085 @default.
• W4324136609 hasConceptScore W4324136609C2777701055 @default.
• W4324136609 hasConceptScore W4324136609C2780057760 @default.
• W4324136609 hasConceptScore W4324136609C71924100 @default.
• W4324136609 hasConceptScore W4324136609C72563966 @default.
• W4324136609 hasFunder F4320332161 @default.
• W4324136609 hasIssue "6_suppl" @default.
• W4324136609 hasLocation W43241366091 @default.
• W4324136609 hasOpenAccess W4324136609 @default.
• W4324136609 hasPrimaryLocation W43241366091 @default.
• W4324136609 hasRelatedWork W2342781363 @default.
• W4324136609 hasRelatedWork W2610751918 @default.
• W4324136609 hasRelatedWork W2777867648 @default.
• W4324136609 hasRelatedWork W2786497694 @default.
• W4324136609 hasRelatedWork W2904110710 @default.
• W4324136609 hasRelatedWork W2969782175 @default.
• W4324136609 hasRelatedWork W3153432702 @default.
• W4324136609 hasRelatedWork W3161613553 @default.
• W4324136609 hasRelatedWork W3215044659 @default.
• W4324136609 hasRelatedWork W4309809336 @default.
• W4324136609 hasVolume "41" @default.
• W4324136609 isParatext "false" @default.
• W4324136609 isRetracted "false" @default.
• W4324136609 workType "article" @default.